Why Mankind Pharma Shares Are Down 2.36% Today | 1 October 2026

NSE: MANKIND · 1 October 2026 · Dated market coverage

Price
₹2,484.90

Change
-2.36%

High / Low
₹2,500.30 / ₹2,477.10

Prev. Close
₹2,545.00

Volume
19.0K

Updated
09:30 AM

Key Takeaways
  • MANKIND PHARMA LIMITED was trading2.36% lowerat ₹2,484.90 and around the middle of the day’s trading range.
  • Likely reason:sector-aligned pullback on light volume.
  • Cash volume was around4% of the 20-day average full-session volume, so participation remained below an average full session.

Why Mankind Pharma Shares Are Falling 2.36% Today

Mankind Pharma Limited shares are trading lower by 2.36% at ₹2,484.90, moving near the lower end of their intraday range between ₹2,477.10 and ₹2,500.30 following a weak opening at ₹2,495.70. Trading volume remains muted compared to normal averages, with current volume sitting significantly below its 5-day and 20-day benchmarks.

The broader market and sectoral indices are also seeing mild negative pressure, with the Nifty down 0.29% and the Nifty Pharma sector index declining by 0.34%. Mankind’s intraday pullback places it broadly in line with the softer sentiment prevailing across pharmaceutical counters during the session.

While recent operational updates include the ongoing process for voluntary liquidation and integration of material subsidiary Bharat Serums and Vaccines Limited alongside statutory auditor changes, these corporate restructuring events provide backdrop context rather than direct catalysts for today’s intraday price move.

Likely Reason for Today’s Move
sector-aligned pullback on light volume
The stock is sliding alongside broader pharmaceutical sector softness amidst low trading volumes, with no single same-day company-specific news catalyst driving the session’s action.
  • Intraday price change of -2.36% matching general pharma sector weakness (-0.34%).
  • Volume is significantly lower than 5-day and 20-day averages.
  • Absence of any immediate same-day fundamental trigger.

Latest Company Developments

Resignation of Statutory Auditors at Material Subsidiary
28-Sep-2026
Mankind Pharma informed the exchanges regarding the resignation of the statutory auditors of Bharat Serums and Vaccines Limited, its material wholly owned subsidiary company. The filing outlines the procedural governance update concerning subsidiary operations.

Board Consent for Voluntary Liquidation of Subsidiary
26-Aug-2026
The board of directors granted consent for the integration of Bharat Serums and Vaccines Limited, a wholly owned material subsidiary, into the parent company by way of voluntary liquidation. This internal restructuring aims to streamline group corporate structures.

Exclusive In-Licensing Agreement for Insulin Portfolio
20-Aug-2026
Mankind Pharma announced an exclusive in-licensing agreement for Insulin Degludec and Insulin Degludec plus Aspart combination products for the Indian market. This move strengthens the company’s anti-diabetic therapeutic franchise.

Ownership & Transaction Activity

Promoter Pledge / Encumbrance
Promoter Holding
72.63%
72.66% previous qtr

Recent Ownership / Shareholding
FII/FPI
9.45%
10.24% previous qtr

Mutual Funds
10.87%
10.36% previous qtr

Institutional
24.84%
24.70% previous qtr

MF Schemes
36
31 previous qtr

Mutual Fund Holdings

Mutual funds increased their aggregate stake to10.87%from 10.36%in the previous quarter. The number of disclosed MF/UTI shareholders was 36, versus 31 in the previous quarter.
NIPPON LIFE INDIA TRUSTEE LTD-A/C NIPPON INDIA NIF
8.55M shares • 2.07%
30-JUN-2026

SBI ARBITRAGE OPPORTUNITIES FUND
6.43M shares • 1.56%
30-JUN-2026

What to Watch Next

  • Progress and timelines regarding the voluntary liquidation and integration of Bharat Serums and Vaccines Limited
  • Commercialization updates regarding the in-licensed insulin portfolio in the Indian anti-diabetic market

Frequently Asked Questions

Why is MANKIND PHARMA LIMITED share price falling today?

The stock is sliding alongside broader pharmaceutical sector softness amidst low trading volumes, with no single same-day company-specific news catalyst driving the session’s action.

How strong is trading participation today?

Participation is moderate rather than exceptional. Volume is about 0.04x the latest 20-day average.

Disclaimer:Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is informational and educational, not personalised investment advice or a recommendation. Market data may be delayed; verify current information before acting.

Other Dated Coverage

More Mankind Pharma news and dated analysis →

Article by: WittyTrades Research Desk

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top